Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M, Kosaka A, Yajima Y, Yasuda S, Ohara M, Ohara K, Harabuchi S, Hayashi R, Funakoshi H, Ueda J, Kumai T, Nagato T, Oikawa K, Harabuchi Y, Esteban C, Ohkuri T, Kobayashi H. Nagata M, et al. Among authors: harabuchi s. Cancer Immunol Immunother. 2021 Aug;70(8):2301-2312. doi: 10.1007/s00262-021-02864-0. Epub 2021 Jan 28. Cancer Immunol Immunother. 2021. PMID: 33507344 Free PMC article.
Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
Harabuchi S, Kosaka A, Yajima Y, Nagata M, Hayashi R, Kumai T, Ohara K, Nagato T, Oikawa K, Ohara M, Harabuchi Y, Ohkuri T, Kobayashi H. Harabuchi S, et al. Biochem Biophys Res Commun. 2020 Feb 5;522(2):408-414. doi: 10.1016/j.bbrc.2019.11.107. Epub 2019 Nov 23. Biochem Biophys Res Commun. 2020. PMID: 31771883
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H. Ohara M, et al. Among authors: harabuchi s. Cancer Immunol Immunother. 2020 Jun;69(6):989-999. doi: 10.1007/s00262-020-02524-9. Epub 2020 Feb 21. Cancer Immunol Immunother. 2020. PMID: 32086539 Free PMC article.
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes.
Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: harabuchi s. J Exp Med. 2021 Nov 1;218(11):e20200792. doi: 10.1084/jem.20200792. Epub 2021 Sep 24. J Exp Med. 2021. PMID: 34559187 Free PMC article.
Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.
Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H. Ohara K, et al. Among authors: harabuchi y, harabuchi s. Oncoimmunology. 2018 Aug 1;7(9):e1466771. doi: 10.1080/2162402X.2018.1466771. eCollection 2018. Oncoimmunology. 2018. PMID: 30510853 Free PMC article.
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y. Nagato T, et al. Among authors: harabuchi y, harabuchi s. Lab Invest. 2019 May;99(5):612-624. doi: 10.1038/s41374-018-0182-9. Epub 2019 Jan 21. Lab Invest. 2019. PMID: 30664711 Free article.
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H. Hirata-Nozaki Y, et al. Among authors: harabuchi s. J Transl Med. 2019 Jun 20;17(1):207. doi: 10.1186/s12967-019-1957-5. J Transl Med. 2019. PMID: 31221178 Free PMC article.
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Hayashi R, et al. Among authors: harabuchi s. Oncoimmunology. 2020 Dec 29;10(1):1856545. doi: 10.1080/2162402X.2020.1856545. Oncoimmunology. 2020. PMID: 33457076 Free PMC article.
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy.
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: harabuchi s. Cancer Sci. 2021 Jul;112(7):2705-2713. doi: 10.1111/cas.14973. Epub 2021 Jun 3. Cancer Sci. 2021. PMID: 34009705 Free PMC article.
13 results